Mesa LaboratoriesMLAB +0.27%77 Debt-to-EBITDA is 5.74 as of Mar. 2026, which is 39% above its 10-year median of 4.13. GuruFocus rates MLAB with a GF Score™ of 77/100 and a GF Value™ of $116.24 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,788 Hardware companies, Mesa Laboratories ranks worse than 68.57% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Mesa Laboratories's Debt-to-EBITDA or its related term are showing as below:
MLAB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.94 Med: 4.13 Max: 6.8
Current: 3.38
During the past 13 years, the highest Debt-to-EBITDA Ratio of Mesa Laboratories was 6.80. The lowest was -0.94. And the median was 4.13.
MLAB's Debt-to-EBITDA is ranked worse than 68.57% of 1788
companies
in the Hardware industry
Industry Median: 1.715
vs MLAB: 3.38
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Mesa Laboratories Debt-to-EBITDA Related Terms
Mesa Laboratories Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Mesa Laboratories's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLAB vs AERG, USBC, MVIS: Debt-to-EBITDA Comparison
For the Scientific & Technical Instruments subindustry, Mesa Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesa Laboratories Debt-to-EBITDA vs Hardware Industry
For the Hardware industry and Technology sector, Mesa Laboratories's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mesa Laboratories's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Mesa Laboratories (MLAB) has a Debt-to-EBITDA of 5.74 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mesa Laboratories. This is 39% above median its historical median of 4.13. According to the industry distribution chart, Mesa Laboratories ranks #1226 out of 1788 companies in the Hardware industry, placing it in the top 68.6%.
Is Mesa Laboratories' Debt-to-EBITDA too high?
Mesa Laboratories' current Debt-to-EBITDA of 5.74 is 39% above median its 10-year median of 4.13. The Hardware industry median Debt-to-EBITDA is 1.72. Mesa Laboratories' value of 5.74 is 234.7% above this industry median. Based on the distribution chart, Mesa Laboratories ranks #1226 out of 1788 companies in the Hardware industry, which is below the industry midpoint. Overall, Mesa Laboratories has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Mesa Laboratories' Debt-to-EBITDA compare to AERG and USBC?
According to the Hardware industry distribution chart, Mesa Laboratories ranks #1226 out of 1788 companies for Debt-to-EBITDA. This places Mesa Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 1.72. Mesa Laboratories' value of 5.74 is 234.7% above this benchmark. While the company's 10-year median is 4.13 vs. the industry median of 1.72, Mesa Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Hardware company?
The median Debt-to-EBITDA among Hardware companies is 1.72, based on 1,788 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mesa Laboratories's current Debt-to-EBITDA of 5.74 is 234.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Mesa Laboratories. For the Hardware industry, the median Debt-to-EBITDA is 1.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesa Laboratories's current Debt-to-EBITDA is 5.74, which is 39% above median its own 10-year median of 4.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Mesa Laboratories (MLAB) is currently considered Modestly Undervalued. The stock's GF Value™ is $116.24, compared to a current price of $95.61 — trading 17.7% below its estimated fair value. The current Debt-to-EBITDA is 5.74, which is 39% above median its 10-year median of 4.13 and 234.7% above the Hardware industry median of 1.72. Mesa Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Mesa Laboratories (MLAB), the current Debt-to-EBITDA is 5.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mesa Laboratories (MLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Mesa Laboratories stock appears to be undervalued.
The current stock price of $95.61 is trading 17.7% below its estimated GF Value™ of $116.24.
GuruFocus considers Mesa Laboratories to be Modestly Undervalued.
Key valuation signals for MLAB:
Debt-to-EBITDA: 5.74 (39% above median its 10-year median of 4.13)
GF Value™: $116.24 vs. price of $95.61 (17.7% below fair value)
Industry Position: 234.7% above the Hardware median (#1226 of 1788)
No single metric tells the full story. See the MLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.
77GF Score
Get the complete analysis for MLAB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLAB has been successfully added to your 
